BERWYN, Pa.--(BUSINESS WIRE)--For biopharmaceutical companies, bringing new drugs to market is costly, time-consuming, and risky. The companies are seeking help from contract research organizations (CROs), which are applying a high level of technical expertise, productivity, and cost savings to drug development. That’s the conclusion of the latest Sector Focus commentary by four health-care sector analysts at Turner Investment Partners.
